WO2007074811A1 - A型インフルエンザウイルス強毒株の検出法 - Google Patents
A型インフルエンザウイルス強毒株の検出法 Download PDFInfo
- Publication number
- WO2007074811A1 WO2007074811A1 PCT/JP2006/325886 JP2006325886W WO2007074811A1 WO 2007074811 A1 WO2007074811 A1 WO 2007074811A1 JP 2006325886 W JP2006325886 W JP 2006325886W WO 2007074811 A1 WO2007074811 A1 WO 2007074811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- influenza
- virus
- reacts
- membrane carrier
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000001514 detection method Methods 0.000 title claims abstract description 29
- 206010022000 influenza Diseases 0.000 title claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 59
- 102000036639 antigens Human genes 0.000 claims abstract description 59
- 108091007433 antigens Proteins 0.000 claims abstract description 59
- 238000003018 immunoassay Methods 0.000 claims abstract description 23
- 239000012528 membrane Substances 0.000 claims description 165
- 241000712431 Influenza A virus Species 0.000 claims description 155
- 238000012360 testing method Methods 0.000 claims description 147
- 108010061100 Nucleoproteins Proteins 0.000 claims description 70
- 102000011931 Nucleoproteins Human genes 0.000 claims description 70
- 241000712461 unidentified influenza virus Species 0.000 claims description 52
- 241001473385 H5N1 subtype Species 0.000 claims description 38
- 239000011259 mixed solution Substances 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 230000001018 virulence Effects 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 22
- 238000002372 labelling Methods 0.000 claims description 21
- 239000000969 carrier Substances 0.000 claims description 19
- 238000005259 measurement Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 12
- 241000252843 H5N2 subtype Species 0.000 claims description 11
- 238000000691 measurement method Methods 0.000 claims description 11
- 208000037797 influenza A Diseases 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 9
- 239000000084 colloidal system Substances 0.000 claims description 8
- 229920000126 latex Polymers 0.000 claims description 7
- 239000004816 latex Substances 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims 1
- 239000002435 venom Substances 0.000 claims 1
- 210000001048 venom Anatomy 0.000 claims 1
- 231100000611 venom Toxicity 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 3
- 210000004379 membrane Anatomy 0.000 description 99
- 239000000523 sample Substances 0.000 description 58
- 208000015181 infectious disease Diseases 0.000 description 34
- 238000003317 immunochromatography Methods 0.000 description 27
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000009257 reactivity Effects 0.000 description 17
- 238000011144 upstream manufacturing Methods 0.000 description 16
- 238000005470 impregnation Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 12
- 235000013330 chicken meat Nutrition 0.000 description 12
- 238000004040 coloring Methods 0.000 description 11
- 241000713196 Influenza B virus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000037798 influenza B Diseases 0.000 description 9
- 210000000628 antibody-producing cell Anatomy 0.000 description 8
- -1 etc.) Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241000197306 H1N1 subtype Species 0.000 description 7
- 241000252870 H3N2 subtype Species 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 241000272525 Anas platyrhynchos Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 208000002979 Influenza in Birds Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010064097 avian influenza Diseases 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 239000003365 glass fiber Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000227653 Lycopersicon Species 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 101150118742 NP gene Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000026425 severe pneumonia Diseases 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000486679 Antitype Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001641735 Cygnus cygnus Species 0.000 description 1
- 241000252866 H7N1 subtype Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940117432 influenza b virus antigen Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229920006173 natural rubber latex Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Definitions
- influenza viruses that have caused highly pathogenic avian influenza are the H5 and H7 subtypes of influenza A virus. Not all of these subtypes are highly toxic, but in Japan, if livestock is infected with these subtypes, regardless of whether they are toxic or weakly toxic, Have been!
- H5 subtypes, H7 subtypes, and H9 subtypes have been reported to infect humans with avian influenza! Of these, deaths were reported due to influenza virus! Only the H5N1 subtype was reported. H5N1 subtype infection has been reported to cause severe pneumonia leading to death.
- the highly pathogenic avian influenza caused by the H5N1 subtype was epidemic in Hong Kong in 1997, and in addition to the power of 2003, it was a pandemic in several Asian powers, and human infections and deaths were reported.
- Influenza virus infects the upper and lower respiratory tracts of humans. After a incubation period of 1 to 2 days, fever (38-39 ° C) and headache, back pain, muscle pain, general malaise, digestive symptoms Cause.
- fever 38-39 ° C
- headache back pain, muscle pain, general malaise, digestive symptoms
- the most common complication of influenza is pneumonia in the elderly and encephalitis in children's encephalopathy, especially encephalitis and encephalopathy in children, characterized by high fever, disturbance of consciousness, and convulsions. Rapid diagnosis and treatment is necessary because the time to onset of symptoms and death is extremely short.
- kits for rapidly detecting influenza virus antigens have been developed and started to spread. It has become possible to diagnose early as an infectious disease. Examples of such rapid diagnosis kits include those that use enzyme immunoassay (EIA) or immunochromatography as the principle, and those that detect only influenza A virus, and detect A and B together. There are some that detect A type and B type.
- influenza antigen tests are common to all types of A viruses Uses antibodies against nucleoproteins. Therefore, differential diagnosis between influenza A virus H5 subtype infection and H1N1 or H3N2 subtype infection is not possible.
- H5N1 subtype infection causes severe pneumonia and has a very high mortality rate.
- Differential diagnosis of H5 subtype infection at the time of initial diagnosis is important in formulating treatment strategies for patients.
- it is possible to take measures such as isolating patients at an early stage to prevent new infections, which is important in preventing further spread of H5N1 subtype infection.
- Patent Document 1 Japanese Translation of Special Publication 2004-509648
- Patent Document 2 Japanese Patent Laid-Open No. 11-108932
- Patent Document 3 Japanese Patent Laid-Open No. 2001-215228
- influenza A virus H5N1 subtype causes severe pneumonia and has a high mortality rate.
- influenza A virus H5 subtype cannot be detected by distinguishing it from other influenza A virus infections using conventional influenza virus antigen detection reagents.
- An object of the present invention is to provide an influenza A virus comprising the influenza A virus H5N1 subtype Providing detection reagents that can quickly and easily differentially diagnose virus virulent strains, and detection methods using them, in particular sandwich immunoassays, especially immunochromatography and immunochromatography measuring devices The purpose is to do. Means for solving the problem
- all influenza A virus variants Does not react to the first antibody that reacts against type A and influenza A virus virulent strains! Reacts to all influenza A subtypes other than the virulent strain
- a third antibody that reacts with an antigen to which the first antibody reacts is prepared by preparing a membrane carrier having first and second capture sites formed by previously immobilizing the second antibody in place. And a first mixture of the test sample and a second mixture of the fourth antibody that reacts with the antigen to which the second antibody reacts and the test sample, respectively. Chromatographic development on the membrane carrier toward the second capture site, or chromatographic development on the membrane carrier toward the both capture sites, and the first mixture is chromatographed on the first carrier. Positive reaction with the first antibody at the capture site and the second capture part I Takeno chromatographic assay reaction with the second antibody is characterized in that to be able to detect Influenza A Virus virulent strain has to be negative is provide in.
- the first antibody that reacts with all influenza A virus subtypes does not react with the influenza A virus virulent strain.
- a second antibody that reacts against all influenza A virus subtypes other than the virulent strain, a third antibody that reacts with an antigen to which the first antibody reacts, and the second antibody At least a fourth antibody that reacts with an antigen to which the antibody reacts, and a membrane carrier, wherein the first and second antibodies are respectively fixed in advance at predetermined positions on the membrane carrier, and Forming a capture site, the third and fourth antibodies are labeled with an appropriate labeling substance, and the third and fourth antibodies are first and second from positions remote from both of the capture sites, respectively.
- Chromatographic development on the membrane carrier toward the second capture site Influenza A virus virulent strain detection I Takeno chromatography measurement device comprising is provided so as.
- the membrane carrier may be a single membrane carrier force comprising a first capture site and a second capture site spaced apart from each other, or the first antibody may be It may be composed of an immobilized first membrane carrier and a second membrane carrier on which the second antibody is immobilized, but the latter is preferred because of its superior reaction specificity.
- the third antibody is prepared on the first membrane carrier
- the fourth antibody is prepared on the second membrane carrier.
- measurement can be performed simply by injecting the test sample into each membrane carrier.
- the third and fourth antibodies are conveniently prepared by impregnating the impregnating members disposed on the first and second membrane carriers, respectively.
- the first antibody that reacts against all influenza A virus subtypes, and the strong poison that does not react against the influenza A virus virulent strain A second antibody that reacts against all influenza A virus subtypes other than the strain, and a third antibody that reacts with an antigen to which the first antibody reacts, A membrane carrier provided with a first capture site formed by fixing in advance at a predetermined position is prepared, a first mixed solution containing the second antibody and a test sample, and the third antibody and the above The second mixed solution containing the test sample is chromatographed on the membrane carrier toward the first capture site, respectively, and the reaction of the third antibody at the first capture site is positive and the second capture solution is positive.
- the membrane carrier may be prepared as a single type of membrane carrier on which the first antibody is immobilized.
- the chromatographic development of the first mixture and the chromatographic development of the second mixture are performed twice. Chromatographic development is required, and a total of two membrane carriers are required for each chromato development.
- a first antibody that reacts against all influenza A virus subtypes, and a sputum that does not react against an influenza A virus virulent strain A second antibody that reacts with all influenza A virus subtypes other than the virulent strain, a third antibody that reacts with an antigen with which the first antibody reacts, and a membrane carrier.
- the first antibody is previously fixed at a predetermined position of the membrane carrier to form a first capture site, and the second and third antibodies are labeled with an appropriate labeling substance, and
- the second and third antibodies are prepared so that they can be chromatographed on the membrane carrier from a position separated from the capture site toward the first capture site, respectively. Provided by chromatography measuring equipment It is.
- the membrane carrier is preferably composed of at least a first membrane carrier to which the first antibody is immobilized and a second membrane carrier to which the first antibody is immobilized.
- the measurement can be performed simply by injecting the test sample into both membrane carriers. This is convenient.
- the second and third antibodies are preferably prepared by impregnating the impregnating members disposed on the first and second membrane carriers, respectively.
- the detection method and measurement method of the present invention include commercially available immunochromatographic test strips or kits for differential measurement of type A and B influenza, such as Capillia (registered trademark) FluA + B (manufactured by Towns Co., Ltd.), It can be carried out in combination with a sandwich immunoassay device using the first antibody and the second antibody.
- Capillia registered trademark
- FluA + B manufactured by Towns Co., Ltd.
- a first antibody that reacts against all influenza A virus subtypes and an influenza A virus virulent strain The at least one second antibody that reacts against all influenza A virus subtypes other than the virulent strain, and a membrane carrier, wherein the second antibody is previously a membrane carrier.
- the first antibody is labeled with an appropriate labeling substance, and is separated from the first capture site to the first capture site.
- the first and second antibodies used in the present invention may be antibodies against influenza viruses, but are usually obtained as antibodies against influenza virus nucleoproteins.
- Each of the first and second antibodies may be a polyclonal antibody or a monoclonal antibody. From the viewpoint of reaction specificity, the first and second antibodies are preferably monoclonal antibodies.
- the first antibody a known monoclonal antibody against the nucleoprotein of influenza A virus can be usually used.
- the second antibody was obtained in the course of studying reactivity against various influenza A virus subtypes, as well as various monoclonal antibodies against the influenza A virus nucleoprotein.
- the above polyclonal antibody is, for example, a DNA corresponding to a portion containing an amino acid residue constituting an epitope in a DNA sequence encoding the amino acid sequence described in SEQ ID NO: 6. Fragments are cloned, the cloned ⁇ gene is genetically expressed in a host such as Escherichia coli, and the expressed protein is extracted and purified. Using this purified protein as an antigen, animals are immunized according to conventional methods and obtained from the antiserum. be able to.
- a DNA fragment corresponding to a portion containing an amino acid residue constituting an epitope different from the influenza virus H5N1 subtype in the DNA sequence encoding the amino acid sequence shown in SEQ ID NO: 6 is used.
- the first antibody and the second antibody for example, after immunizing an animal such as a mouse using the purified protein obtained as described above as an antigen, spleen cells and myeloma cells of the immunized animal are used.
- the fused cells obtained by cell fusion are selected with a HAT-containing medium and grown, and the grown strain is selected using the purified protein obtained as described above, for example, by enzyme-labeled immunization. By doing so, it can be obtained.
- the monoclonal antibody used as the second antibody does not react with an influenza A virus virulent strain, but is against all influenza A subtypes other than the virulent strain.
- Reactive monoclonal antibodies especially stored in all influenza A viruses except influenza virus virulence strains !, but epitopes that have been mutated and disappeared in influenza virus virulence strains, especially type A It recognizes the epitope of influenza virus nuclear protein.
- the influenza A virus epitope is mutated due to the substitution force of the amino acid sequence or the occurrence of a different sugar chain modification in the influenza virus H5N1. It is thought that it is not specifically recognized by.
- Such a monoclonal antibody has not been known so far and is novel.
- the present invention does not react against an influenza A virus virulent strain, but reacts against all influenza A virus subtypes other than the virulent strain.
- Monoclonal antibodies are provided.
- the monoclonal antibody does not react with the influenza A virus H5N1 subtype nucleoprotein, but reacts with all the influenza A virus subtype nucleoproteins other than the H5N1 subtype.
- the fourth antibody used in the sandwich immunoassay method such as the immunochromatography method may be an antibody that reacts with the antigen to which the second antibody reacts. It may be the same antibody as the second antibody or an antibody other than the second antibody. For example, when the antigen comprises a plurality of epitopes for the second antibody, the same antibody as the second antibody can be used as the fourth antibody. Therefore, the fourth antibody may be an antibody that reacts against all influenza A virus subtypes, or it may not react with an influenza A virus virulent strain but other than the virulent strain. It may be an antibody that reacts with all types of influenza A virus subtypes. The fourth antibody may be a monoclonal antibody or a polyclonal antibody.
- the membrane carrier 3 is composed of an elongated strip-trocellulose membrane filter having a width of 5 mm and a length of 36 mm, and is attached to the middle of the adhesive sheet 1 having the same width.
- the membrane carrier 3 has its chromatographic start point side, that is, the left side in FIG. 1 (hereinafter referred to as “upstream side”.
- the opposite side that is, the chromatographic development direction side in FIG.
- the first antibody is immobilized at a position of 7.5 mm downstream from the end of the terminal, and captures the complex of the third antibody and a virus antigen such as a nucleoprotein of influenza A virus.
- a first capture site 41a is formed.
- a 5 mm ⁇ 15 mm band-shaped glass fiber nonwoven fabric is used as the impregnating member 2, but the invention is not limited to this.
- cellulose cloth filter paper, nitrocellulose membrane, etc.
- polyethylene Also, porous plastic cloth such as polypropylene can be used.
- the labeling substance for the third and fourth antibodies include a color labeling substance, an enzyme labeling substance, a radiation labeling substance, etc., as long as they are usable. Of these, it is preferable to use a colored labeling substance because it can be quickly and easily determined by observing the color change at the capturing site 4 with the naked eye.
- coloring labeling substance examples include metal colloids such as gold colloid and platinum colloid, synthetic latex such as polystyrene latex colored with pigments such as red and blue, and latex such as natural rubber latex. Of these, metal colloids such as gold colloid are particularly preferred.
- the immunochromatographic test strip 10 has a membrane carrier 3 stuck in the middle of the pressure-sensitive adhesive sheet 1, and the impregnation member 2 is placed on the upstream end of the membrane carrier 3.
- the downstream end can be overlapped and connected, and the upstream portion of the impregnated member 2 can be attached to the adhesive sheet 1 to create.
- Absorbing member 5 can be made of cotton cloth, filter paper, and porous plastic non-woven fabric that has strength such as polyethylene and polypropylene as long as it is made of a material that can absorb and hold liquid quickly. Filter paper is particularly suitable. .
- the immunochromatographic test strip 10 of FIG. 1 can be used as it is as a dipstick type measuring device, or alternatively, provided as a dipstick type measuring device lined or sandwiched with an appropriate plastic sheet. You can do it.
- the immunochromatographic test strip 10 shown in FIG. 1 is provided as a measuring device housed in a suitable plastic case with a test sample injection part and a judgment part opened above the sample addition member 6 and the capture part 4, respectively.
- the third and fourth antibodies are mixed with a test sample and a developing solvent in a suitable container separate from the immunochromatographic test strip 10, and then mixed.
- the detection sensitivity of the second capture site 41b tends to decrease.
- the sensitivity is preferably adjusted by a method such as increasing the amount of antibody immobilized on 41b to be greater than the amount of antibody immobilized on the first capture site 41a.
- test sample is not particularly limited, but, for example, Cloacas tube, tracheal tube, feces, nasal aspirate, nasal and throat swabs, blood (can be whole blood, serum, or plasma), Saliva, urine, organ emulsions and the like can be mentioned.
- the test sample may be diluted with an appropriate diluent such as a developing solvent and injected into the membrane carrier.
- a blood cell capturing membrane member When whole blood is used as a test sample, particularly when a colored labeling substance such as gold colloid is used as the labeling substance of the labeled antibody, a blood cell capturing membrane member may be disposed on the sample addition member. preferable.
- the blood cell trapping membrane member is preferably laminated between the impregnation member and the sample-added calorie member. This prevents the red blood cells from being spread on the membrane carrier, thereby facilitating confirmation of the accumulation of the colored label at the capture site of the membrane carrier.
- a carboxymethyl cellulose membrane is used as the blood cell capturing membrane member.
- the ion exchange filter paper CM (trade name) sold by Advantech Toyo Co., Ltd. or the Whatman Japan Co., Ltd.! An exchange cellulose paper etc. can be used.
- the mixed solution is added to each of the immunochromatographic test strips 10 and 20 shown in FIG.
- the mixed solution passes through the sample addition member 6 and mixes with the labeled antibody in the impregnation member 2.
- the immunochromatographic test strip 10 forms a complex of the virus antigen and anti-B influenza virus antibody by the antigen-antibody reaction. .
- This complex is chromatographed in the membrane carrier 3 to reach the capture site 4 and is captured by an antigen-antibody reaction with the anti-influenza B virus antibody immobilized at 4 lb of the capture site, giving a positive result.
- the first capture site 41a is not captured by the immobilized first antibody and gives a negative result.
- a complex of the virus antigen and the fourth antibody is not formed, and both of them are independently chromatographed in the membrane carrier 3 to reach the second capture site 41c. Is not captured by the second antibody immobilized thereon but gives a negative result.
- the infection is a highly virulent strain, an influenza A virus other than a virulent strain, or an influenza B virus infection Can be identified.
- the immunochromatographic test strip 10 shown in FIG. 2 a commercially available immunochromatographic test strip or kit for differential measurement of influenza A and B influenza such as Capilia (registered trademark) FluA + B (manufactured by Towns Co., Ltd.) is used. It can also be used as it is. Therefore, only the immunochromatographic test strip 20 of FIG. 2 can be supplied separately so that the detection method or measurement method of the present invention can be carried out in combination with such a commercially available test strip or kit.
- Capilia registered trademark FluA + B
- the immunochromat test strip 10 exhibits a positive result at the first capture site 41a as in FIG. 4 lb gives a negative result.
- the immunochromatographic test strip 20 a complex was formed between the virulent strain virus antigen and the labeled antibody, but it was not captured by the second antibody immobilized at the second capture site 41c, resulting in a negative result.
- influenza A virus other than the virulent strain is present in the mixed solution, the immunochromatographic test strip 10 gives a positive result at the first capture site 41 as in FIG. 2, but the capture site 41b Shows a negative result.
- the immunochromatographic test strip 20 a complex of the virus antigen and the labeled antibody is formed, and is chromatographed in the membrane carrier 3 to reach the second capture site 41c, where it is fixed to the second capture site 41c. It is captured by the antibody and gives a positive result.
- the susceptibility of the virulence strain or the sensitivity of influenza A virus other than the virulence strain It can be discriminated whether it is infected with dyed influenza B virus.
- the device of FIG. 3 may be in the form of being housed in a suitable case.
- the apparatus of Fig. 4 has the same configuration as that of Fig. 2 except that the immunochromatographic test strips 10 and 20 include a single adhesive tape 1 and a single sample addition member 6. Yes. That is, both membrane carriers 3 of the immunochromatographic test strips 10 and 20 are arranged substantially in a straight line so as to face each other. Specifically, the immunochromatographic test strips 10 and 20 are arranged in a straight line so that the upstream ends of the two impregnated members 2 face each other with an appropriate interval, that is, in opposite directions.
- the single sample addition member 6 is arranged so as to be connected across both the impregnating members 2. Alternatively, the membrane supports of the immunochromatographic test strips 10 and 20 may be arranged radially so that they extend at an angle to each other.
- the mixed solution After preparing a mixed solution containing the test sample in the same manner as described above with reference to FIG. 2, add the common sample to the immunochromatographic test strips 10 and 20 shown in FIG. When injected on the member 6, the mixed solution passes through the sample addition member 6 and is mixed with the labeled antibody in the impregnating member 2 of both test strips 10 and 20.
- the result of the first capture site 41a, the second capture site 41c, and the capture site 41b indicates whether the infection is a virulent strain or an influenza A virus other than the virulent strain. It can be discriminated whether it is influenza B virus infection.
- the apparatus of FIG. 4 may be configured to be housed in a suitable case.
- the impregnation member 2 may be common to the test strips 10 and 20.
- the third and fourth antibodies can be constructed according to the embodiment of FIG.
- the apparatus shown in FIG. 4 adjusts the sensitivity of the first and second capture sites 41a and 41b as the apparatus shown in FIG. 1 because the mixed solution containing the test sample penetrates the test strips 10 and 20 evenly. Convenient in terms of not necessary.
- the apparatus of FIG. 2 can be modified to an apparatus for carrying out the embodiment of the present invention using the second antibody as a labeled antibody.
- Such an apparatus is the same as that shown in FIG.
- the first antibody is immobilized on the second capture site 41c of the test strip 20, and the first antibody is used instead of the fourth antibody as the labeled antibody to be impregnated in the impregnation member 2 of the strip 20.
- It can be constructed by using two antibodies.
- the structure of the Imunoguchi-Mato test strip 10 is exactly the same as that of FIG.
- the immunochromatographic test strip 10 gives a positive result at the first capture site 41 as in FIG. 2, but the capture site 41b Shows a negative result.
- the immunochromatographic test strip 20 a complex of the virus antigen and the labeled antibody is formed, and is chromatographed in the membrane carrier 3 to reach the capture site 41.
- the first capture site 41c It is captured by the antibody and gives a positive result.
- the apparatus in FIG. 4 can also be modified to an apparatus for carrying out the embodiment of the present invention using the second antibody as a labeled antibody by making the same changes as described above. That is, in the apparatus of FIG. 4, the first antibody is immobilized in place of the second antibody at the second capture site 41c of the immunochromatographic test strip 20, and the labeling antibody impregnated in the impregnation member 2 of the strip 20 is immobilized.
- the body can be modified by using the second antibody instead of the fourth antibody.
- the structure of the immunochromatographic test strip 10 is exactly the same as that shown in FIG.
- the mixed solution After preparing a mixed solution containing the test sample by the same method as described above with reference to FIG. 2, the mixed solution is applied to the modified immunochromatographic test strips 10 and 20 of FIG. When injected onto the common sample addition member 6, the mixed solution passes through the sample addition member 6 and is mixed with the labeled antibody in the impregnation member 2 of both test strips 10 and 20.
- the result of the first capture site 41a, the second capture site 41c, and the capture site 41b indicates whether the virulence strain is infected or A-type influenza other than the virulence strain. It is possible to differentiate between the infectivity of enza virus and the infection with influenza B virus.
- Example 1 (Cloning of recombinant nucleoprotein (NP) genes of influenza A and B viruses)
- a / Puerto Rico / 8/34 (H1N1), which is influenza virus type A
- B / Lee / 40 which is influenza virus type B
- RNA extraction reagent (TRIzol Reagent, Invitrogen) was added to this virus to extract each viral RNA.
- a reverse transcription reaction was performed from the extracted RNA to prepare an NP gene cDNA.
- Uni 12 Primer: 5′-AGCAAAAGCAGG-3, (SEQ ID NO: 1) was used as a primer used for the reverse transcription reaction.
- influenza A virus recombinant NP protein (FluA NP) and influenza B virus recombinant NP protein (FluB NP) obtained in Example 2 as antigens
- monoclonal antibodies against anti-FluA NP and FluB NP (anti-FluA NP antibody and Anti-FluB NP antibody) was created.
- Production of the monoclonal antibody was performed according to a conventional method.
- Each 100 g of recombinant NP protein and equal amount of Adjuvant Complete Freund (Difco) were mixed, and mice (BALB / c, 5 weeks old, Japan SLC) were immunized 3 times, and the spleen cells were used for cell fusion. Using.
- Sp2 / 0-Agl4 cells (Shulman et al., 1978), mouse myeloma cells, were used for cell fusion.
- Dulbecco's Modified Eagle Medium (Gibco) L-glutamine 0 • 3 mg / ml
- penicillin G potassium 100 units / ml
- streptomycin sulfate 100 ⁇ g / ml
- gentacin 40 ⁇ g / ml gentacin 40 ⁇ g / ml
- JRH fetal calf serum
- Antibody production in the culture supernatant was confirmed by enzyme-linked antibody method (ELISA) using A (H1N1) immobilized plate, and inactivated Influenza B virus was used as a solid phase for screening of anti-FluB NP antibody.
- ELISA enzyme-linked antibody method
- the antibody production in the culture supernatant was confirmed by the same method using the prepared plate.
- anti-F1 uA NP antibody-producing cells F / 211 were inoculated into the peritoneal cavity of mice, and ascites containing anti-FluA NP antibody was obtained. Furthermore, IgG was purified using a protein G adsorbent by a conventional method to obtain each antibody.
- Anti-FluA NP antibody derived from antibody-producing cell B / 347 obtained in (1) above (hereinafter referred to as anti-FluA NP antibody B / 347), anti-FluB NP antibody derived from antibody-producing cell F / 171 (hereinafter referred to as anti-FluB) NP antibody F / 171) and anti-FluA NP antibody derived from antibody-producing cell F / 211 (hereinafter, anti-FluA NP antibody F / 21 1) were labeled with colloidal gold according to the following procedure.
- This colloidal gold-labeled antibody was suspended in 50 mM Tris-HCl buffer (PH7.4) containing 10% sucrose '1% BSA' 0.5% Triton-X100 and colloidal gold-labeled anti-FluA NP antibody B / 347 A solution was prepared. Further, 1 ⁇ g of protein equivalent weight of anti-FluB NP antibody F / 171 was bound to the surface of gold colloid particles by the above method to prepare a colloidal gold labeled anti-FluB NP antibody F / 171 solution. Furthermore, 1 ⁇ g of protein equivalent weight of anti-FluA NP antibody F / 211 was bound to the gold colloid particle surface by the above method. A colloidal gold-labeled anti-FluA NP antibody F / 211 solution was prepared.
- Example 4 Using the immunochromatography measuring apparatus prepared in Example 4, reactivity tests against 15 subtypes of type A influenza virus were performed.
- a test sample a chorioallantoic fluid obtained by proliferating various subtypes of type A influenza virus in the laying eggs was prepared using a sample dilution solution. Then, the test sample 1501 was dropped with a micropipette onto the sample addition member 6 of the test strip obtained in Example 4 and chromatographed. After standing at room temperature for 15 minutes, the first capture site 41a and The captured amount of the complex of the virus antigen captured at the second capture site 41c and the colloidal gold labeled antibody was observed with the naked eye. The amount of capture is increased or decreased in proportion to the amount of reddish purple. (No coloration), Shi (weak coloration), + (clear coloration), + + (clearer coloration) , + + + (Significant coloration) was classified into five stages.
- the immunochromatographic measuring apparatus described in Example 4 shows reactivity with all influenza virus types A at the first capture site 41a, and at the second capture site 41c. It was found that there was no reactivity with influenza virus H5N1 only! This is because anti-FluA NP antibody F / 211 used as the labeled antibody of test strip 20 does not react with influenza A virus H5N 1 subtype, but all influenza A except for H5N 1 subtype It indicates that the antibody reacts against a virus subtype.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007551980A JP5432453B2 (ja) | 2005-12-26 | 2006-12-26 | A型インフルエンザウイルス強毒株の検出法 |
US12/159,115 US20100267006A1 (en) | 2005-12-26 | 2006-12-26 | Method for detection of cirulent strain of influenza type-a virus |
CA002634968A CA2634968A1 (en) | 2005-12-26 | 2006-12-26 | Method for detection of virulent strain of influenza type-a virus |
AU2006329276A AU2006329276B2 (en) | 2005-12-26 | 2006-12-26 | Method for detection of virulent strain of influenza type-A virus |
EP06843270A EP1970707A4 (en) | 2005-12-26 | 2006-12-26 | METHOD FOR DETECTION OF A VIRULENT STRAIN OF THE INFLUENZA VIRUS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005373584 | 2005-12-26 | ||
JP2005-373584 | 2005-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007074811A1 true WO2007074811A1 (ja) | 2007-07-05 |
Family
ID=38218031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/325886 WO2007074811A1 (ja) | 2005-12-26 | 2006-12-26 | A型インフルエンザウイルス強毒株の検出法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100267006A1 (ja) |
EP (1) | EP1970707A4 (ja) |
JP (1) | JP5432453B2 (ja) |
CN (1) | CN101336375A (ja) |
AU (1) | AU2006329276B2 (ja) |
CA (1) | CA2634968A1 (ja) |
WO (1) | WO2007074811A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010261912A (ja) * | 2009-05-11 | 2010-11-18 | Bl:Kk | ヒトインフルエンザウイルスh3亜型の免疫学的検出法 |
EP2309264A1 (en) * | 2008-06-06 | 2011-04-13 | National University Corporation University Of Toyama | Device for detection of influenza virus |
JP2012112879A (ja) * | 2010-11-26 | 2012-06-14 | National Center For Global Health & Medicine | 免疫検査試薬、それを用いる検査装置及び検査方法 |
CN105403700A (zh) * | 2012-04-05 | 2016-03-16 | 株式会社比尔生命 | 结核菌群的免疫学检测方法和试剂盒 |
JP6469937B1 (ja) * | 2018-03-30 | 2019-02-13 | 株式会社バイオメディカル研究所 | 検査キットおよび検査方法 |
WO2019187271A1 (ja) * | 2018-03-30 | 2019-10-03 | 株式会社バイオメディカル研究所 | 検査キットおよび検査方法 |
JP2020147503A (ja) * | 2019-03-11 | 2020-09-17 | パナソニックIpマネジメント株式会社 | 抗体、複合体、それを用いた検出装置及び検出方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226429B2 (en) | 2003-01-17 | 2007-06-05 | Aethlon Medical, Inc. | Method for removal of viruses from blood by lectin affinity hemodialysis |
CN103917638A (zh) * | 2011-09-08 | 2014-07-09 | Nexusdx股份有限公司 | 多级分析物检定 |
CN103483448B (zh) * | 2012-06-08 | 2017-09-08 | 厦门大学 | 特异结合高致病性禽流感病毒的抗体 |
KR101587645B1 (ko) * | 2014-07-08 | 2016-01-22 | 주식회사 녹십자엠에스 | 멀티 인플루엔자 검출용 키트 및 이를 이용하여 인플루엔자를 검출하는 방법 |
CN108802402A (zh) * | 2018-06-15 | 2018-11-13 | 重庆大学 | 一种快速鉴别呼吸道感染类型的试剂盒及其应用 |
CN113049818A (zh) * | 2021-01-11 | 2021-06-29 | 广东菲鹏生物有限公司 | 一种鉴别突变型抗原的方法及试剂 |
CN113777299B (zh) * | 2021-09-15 | 2023-07-21 | 杭州宝临生物科技有限公司 | 免疫层析检测试剂条包含其的试剂盒及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11108932A (ja) | 1997-08-04 | 1999-04-23 | Tonen Corp | ウイルスの検出又は測定方法 |
JP2000253876A (ja) * | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
JP2004509648A (ja) | 2000-10-05 | 2004-04-02 | ホンコン ディーエヌエー チップス リミティド | 非病原性又は病原性インフルエンザaサブタイプh5ウイルス検出キット |
WO2005007697A1 (ja) | 2003-07-23 | 2005-01-27 | Fujirebio Inc. | 抗インフルエンザa型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具 |
JP2006067979A (ja) * | 2004-09-06 | 2006-03-16 | Bl:Kk | インフルエンザa型ウイルスの免疫検出法 |
JP2006265197A (ja) * | 2005-03-25 | 2006-10-05 | Daikin Ind Ltd | 抗原性人工ポリペプチド |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1081496A1 (en) * | 1999-08-31 | 2001-03-07 | Becton, Dickinson and Company | Flow-through assay for visually detecting the presence of influenza A and B |
US20040265800A1 (en) * | 2003-06-30 | 2004-12-30 | Sysmex Corporation | Sample pretreatment solution for immunological test and method for using the same |
-
2006
- 2006-12-26 JP JP2007551980A patent/JP5432453B2/ja active Active
- 2006-12-26 CN CNA2006800523915A patent/CN101336375A/zh active Pending
- 2006-12-26 WO PCT/JP2006/325886 patent/WO2007074811A1/ja active Application Filing
- 2006-12-26 CA CA002634968A patent/CA2634968A1/en not_active Abandoned
- 2006-12-26 US US12/159,115 patent/US20100267006A1/en not_active Abandoned
- 2006-12-26 EP EP06843270A patent/EP1970707A4/en not_active Withdrawn
- 2006-12-26 AU AU2006329276A patent/AU2006329276B2/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11108932A (ja) | 1997-08-04 | 1999-04-23 | Tonen Corp | ウイルスの検出又は測定方法 |
JP2001215228A (ja) | 1997-08-04 | 2001-08-10 | Sentan Seimei Kagaku Kenkyusho:Kk | ウイルスの検出又は測定方法 |
JP2000253876A (ja) * | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
JP2004509648A (ja) | 2000-10-05 | 2004-04-02 | ホンコン ディーエヌエー チップス リミティド | 非病原性又は病原性インフルエンザaサブタイプh5ウイルス検出キット |
WO2005007697A1 (ja) | 2003-07-23 | 2005-01-27 | Fujirebio Inc. | 抗インフルエンザa型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具 |
JP2006067979A (ja) * | 2004-09-06 | 2006-03-16 | Bl:Kk | インフルエンザa型ウイルスの免疫検出法 |
JP2006265197A (ja) * | 2005-03-25 | 2006-10-05 | Daikin Ind Ltd | 抗原性人工ポリペプチド |
Non-Patent Citations (4)
Title |
---|
HINSHAW V.S. ET AL.: "Specific antibody responses and generation of antigenic variants in chickens immunized against a virulent avian influenza virus", AVIAN DIS., vol. 34, no. 1, 1990, pages 80 - 6 |
KAVERIN N.V. ET AL.: "Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation escape mutants", J. GEN. VIROL., vol. 83, 2002 |
PHILPOTT: "Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza viruses and their relationship to pathogenicity", J. VIROL., vol. 63, no. 8, August 1989 (1989-08-01), pages 3453 - 3458, XP003002755 * |
See also references of EP1970707A4 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2309264A1 (en) * | 2008-06-06 | 2011-04-13 | National University Corporation University Of Toyama | Device for detection of influenza virus |
JPWO2009148150A1 (ja) * | 2008-06-06 | 2011-11-04 | 国立大学法人富山大学 | インフルエンザウィルス検出用デバイス |
EP2309264A4 (en) * | 2008-06-06 | 2011-11-23 | Univ Toyama Nat Univ Corp | FLU VIRUS DETECTION DEVICE |
JP2010261912A (ja) * | 2009-05-11 | 2010-11-18 | Bl:Kk | ヒトインフルエンザウイルスh3亜型の免疫学的検出法 |
JP2012112879A (ja) * | 2010-11-26 | 2012-06-14 | National Center For Global Health & Medicine | 免疫検査試薬、それを用いる検査装置及び検査方法 |
CN105403700A (zh) * | 2012-04-05 | 2016-03-16 | 株式会社比尔生命 | 结核菌群的免疫学检测方法和试剂盒 |
JP6469937B1 (ja) * | 2018-03-30 | 2019-02-13 | 株式会社バイオメディカル研究所 | 検査キットおよび検査方法 |
WO2019187271A1 (ja) * | 2018-03-30 | 2019-10-03 | 株式会社バイオメディカル研究所 | 検査キットおよび検査方法 |
JP2020147503A (ja) * | 2019-03-11 | 2020-09-17 | パナソニックIpマネジメント株式会社 | 抗体、複合体、それを用いた検出装置及び検出方法 |
JP7308477B2 (ja) | 2019-03-11 | 2023-07-14 | パナソニックIpマネジメント株式会社 | 抗体、複合体、それを用いた検出装置及び検出方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5432453B2 (ja) | 2014-03-05 |
EP1970707A4 (en) | 2009-06-17 |
AU2006329276A1 (en) | 2007-07-05 |
EP1970707A1 (en) | 2008-09-17 |
JPWO2007074811A1 (ja) | 2009-06-04 |
AU2006329276B2 (en) | 2012-09-27 |
US20100267006A1 (en) | 2010-10-21 |
CA2634968A1 (en) | 2007-07-05 |
CN101336375A (zh) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5849065B2 (ja) | A型インフルエンザウイルスh5亜型の検出法 | |
JP5432453B2 (ja) | A型インフルエンザウイルス強毒株の検出法 | |
EP2063270B1 (en) | Rapid diagnosis method specific to avian influenza virus | |
AU2008297594B2 (en) | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof | |
US8444986B2 (en) | Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof | |
JP5435844B2 (ja) | インフルエンザウイルスh5亜型の免疫検出法 | |
JP5827701B2 (ja) | インフルエンザウイルスh5亜型の免疫検出法 | |
JP2010261912A (ja) | ヒトインフルエンザウイルスh3亜型の免疫学的検出法 | |
JP2011069800A (ja) | ヒトインフルエンザウイルスh1亜型の免疫学的鑑別検出法 | |
AU2013224734A1 (en) | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007551980 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2634968 Country of ref document: CA Ref document number: 12159115 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5878/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006843270 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006329276 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052391.5 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006329276 Country of ref document: AU Date of ref document: 20061226 Kind code of ref document: A |